Compare KEX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEX | BLTE |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 1994 | 2021 |
| Metric | KEX | BLTE |
|---|---|---|
| Price | $124.29 | $156.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $174.71 | ★ $227.44 |
| AVG Volume (30 Days) | ★ 670.0K | 134.3K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.92 | N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $23.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.10 | $105.88 |
| 52 Week High | $157.69 | $200.00 |
| Indicator | KEX | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 51.94 |
| Support Level | $118.72 | $145.61 |
| Resistance Level | $142.04 | $158.76 |
| Average True Range (ATR) | 5.76 | 7.01 |
| MACD | -1.95 | 1.33 |
| Stochastic Oscillator | 19.45 | 73.84 |
Kirby Corp is a domestic tank barge operator, transporting bulk liquid products throughout three United States coasts. The Company transports petrochemicals, liquid cargoes, inland waterway systems, and dry bulk cargoes. The Company conducts operations in two reportable business segments: The Marine transportation segment which provides marine transportation services, operating tank barges and towing vessels transporting bulk liquid products, and the Distribution and services segment, which provides after-market service, and genuine replacement parts for engines, transmissions, reduction gears, and power generation equipment used in oil and gas and commercial and industrial applications. The company's majority revenue is generated from the Marine Transportation segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.